A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions.
Recombinant interleukin-2 (rIL-2) (NSC# 600664; Hoffmann-La Roche, Inc., Nutley, NJ) was studied in a phase I clinical trial in 33 patients with advanced, measureable cancer of the colon or malignant melanoma, Eastern Cooperative Oncology Group (ECOG) performance status O-1, and no prior chemotherapy or radiotherapy. The goal of the study was to identify a dose and schedule of IL-2 to generate maximal immune modulation with tolerable toxicity. Such a regimen might allow the addition of other treatment modalities and/or prolonged treatment duration in later trials. Each patient received IL-2 as a continuous 24-hour infusion once weekly for 4 weeks and then twice weekly for 4 weeks. Five treatment groups received from 10(3) U/m2 to 3 x 10(7) U/m2 per 24-hour infusion. The maximal tolerated dose was 3 x 10(7) U/m2/d twice weekly. Patients treated twice weekly at 1 x 10(7) and 3 x 10(7) U/m2/d had immune modulation in terms of lymphocytosis, eosinophilia, increased natural killer (NK) activity, and elevated numbers of peripheral blood mononuclear cells expressing CD16, OKT10/Leu-17, and Leu-19 surface markers. Endogenous generation of peripheral blood lymphokine-activated killer (LAK) activity was demonstrated by lysis of NK-resistant Daudi targets, in patients treated at 3 x 10(7) U/m2/d. Biochemical and hematological abnormalities were moderate and reversible. Clinical toxicity included hypotension, myalgia, arthralgia, stomatitis, fever, fatigue, nausea, headache, chills, diarrhea, and oliguria at high doses. Cardiovascular toxicity was tolerable for most patients and reversed after IL-2 was stopped. Two of six melanoma patients at 3 x 10(7) U/m2/d achieved partial responses by the end of the eighth week. This IL-2 schedule appears to produce potentially clinically useful immune enhancement with tolerable toxicity.
Biological Resources Branch, NCI, Frederick, MD 21701-1013.
S P
SP
Creekmore
J E
JE
Harris
T M
TM
Ellis
D P
DP
Braun
I I
II
Cohen
N
N
Bhoopalam
P F
PF
Jassak
M A
MA
Cahill
C L
CL
Canzoneri
R I
RI
Fisher
D000293:Adolescent; D000310:Adrenal Gland Neoplasms / Q000556:secondary / Q000628:therapy; D000328:Adult; D000368:Aged; D003110:Colonic Neoplasms / Q000628:therapy; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D006801:Humans; D007262:Infusions, Intravenous; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000009:adverse effects; D007694:Killer Cells, Natural / Q000187:drug effects; D007958:Leukocyte Count / Q000187:drug effects; D008214:Lymphocytes / Q000145:classification / Q000187:drug effects; D008545:Melanoma / Q000628:therapy; D008875:Middle Aged; D009369:Neoplasms / Q000628:therapy*; D012878:Skin Neoplasms / Q000628:therapy
D007376:Interleukin-2